Trials / Completed
CompletedNCT02935335
A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®
Relationship Between antimüllerian Hormone Measured by a Fully Automated Assay and the Initial Dose of HP-hMG (Menopur®) Prescribed for Infertile Women Undergoing Their First IVF/ICSI Cycle.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 297 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 42 Years
- Healthy volunteers
- Not accepted
Summary
AME is a non-interventional, prospective, longitudinal and multicenter study. This study aims to measure the relationship between antimüllerian hormone serum level (AMH), as measured by a fully automated assay and the initial dose of Menopur® HP-hMG 600 IU/mL prescribed for infertile women undergoing their first IVF/ICSI cycle in the current practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Menotrophin |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-01-31
- Completion
- 2018-06-19
- First posted
- 2016-10-17
- Last updated
- 2019-03-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02935335. Inclusion in this directory is not an endorsement.